These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33858011)

  • 1. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn's Disease, a Randomised Controlled Trial.
    Naftali T; Bar-Lev Schleider L; Almog S; Meiri D; Konikoff FM
    J Crohns Colitis; 2021 Nov; 15(11):1799-1806. PubMed ID: 33858011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study.
    Naftali T; Bar-Lev Schleider L; Dotan I; Lansky EP; Sklerovsky Benjaminov F; Konikoff FM
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1276-1280.e1. PubMed ID: 23648372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.
    Naftali T; Mechulam R; Marii A; Gabay G; Stein A; Bronshtain M; Laish I; Benjaminov F; Konikoff FM
    Dig Dis Sci; 2017 Jun; 62(6):1615-1620. PubMed ID: 28349233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.
    Naftali T; Bar-Lev Schleider L; Scklerovsky Benjaminov F; Konikoff FM; Matalon ST; Ringel Y
    PLoS One; 2021; 16(2):e0246871. PubMed ID: 33571293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Inflamm Bowel Dis; 2020 Mar; 26(4):502-509. PubMed ID: 31613959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cannabinoids in mild-to-moderate cases of Crohn's disease as compared to placebo: a systematic review and meta-analysis of randomised controlled trials.
    Kumar R; Singh S; Maharshi V
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):15-24. PubMed ID: 38409768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chaves C; Bittencourt PCT; Pelegrini A
    Pain Med; 2020 Oct; 21(10):2212-2218. PubMed ID: 33118602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.